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Summary
Background Malaria infection during pregnancy is associated with serious adverse maternal and birth outcomes. A 
randomised controlled trial in Papua, Indonesia, comparing the efficacy of intermittent preventive treatment with 
dihydroartemisinin-piperaquine with the current strategy of single screening and treatment showed that intermittent 
preventive treatment is a promising alternative treatment for the reduction of malaria in pregnancy. We aimed to 
estimate the incremental cost-effectiveness of intermittent preventive treatment with dihydroartemisinin-piperaquine 
compared with single screening and treatment with dihydroartemisinin-piperaquine.
Methods We did a provider perspective analysis. A decision tree model was analysed from a health provider perspective 
over a lifetime horizon. Model parameters were used in deterministic and probabilistic sensitivity analyses. 
Simulations were run in hypothetical cohorts of 1000 women who received intermittent preventive treatment or 
single screening and treatment. Disability-adjusted life-years (DALYs) for fetal loss or neonatal death, low birthweight, 
moderate or severe maternal anaemia, and clinical malaria were calculated from trial data and cost estimates in 2016 
US dollars from observational studies, health facility costings and public procurement databases. The main outcome 
measure was the incremental cost per DALY averted.
Findings Relative to single screening and treatment, intermittent preventive treatment resulted in an incremental cost 
of US$5657 (95% CI 1827 to 9448) and 107·4 incremental DALYs averted (–719·7 to 904·1) per 1000 women; the 
average incremental cost-effectiveness ratio was $53 per DALY averted.
Interpretation Intermittent preventive treatment with dihydroartemisinin-piperaquine offers a cost-effective 
alternative to single screening and treatment for the prevention of the adverse effects of malaria infection in pregnancy 
in the context of the moderate malaria transmission setting of Papua. The higher cost of intermittent preventive 
treatment was driven by monthly administration, as compared with single-administration single screening and 
treatment. However, acceptability and feasibility considerations will also be needed to inform decision making.
Funding Medical Research Council, Department for International Development, and Wellcome Trust.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access Article under the CC BY-NC-ND 
4.0 license.
Introduction
70% of all pregnancies in malaria-endemic regions 
globally are in the Asia-Pacific region, of which an 
estimated 6·4 million pregnancies (5·1% of the global 
total) occur annually in Indonesia, in areas with 
Plasmodium falciparum or Plasmodium vivax trans-
mission.1 Malaria infection in pregnancy is associated 
with serious adverse maternal and birth outcomes. The 
clinical effects of malaria infection in pregnancy depend 
upon the intensity of transmission, the malaria species, 
and the immunity in pregnant women. Indonesia has a 
high heterogeneity of risk of infection and malaria 
incidence across its 6000 inhabited islands.2 Both 
P falciparum and P vivax contribute to the burden of 
malaria infection in pregnancy in Indonesia and both 
infections are associated with severe maternal anaemia, 
fetal loss, and low birthweight.3–5
The harmful effects of malaria infection in pregnancy 
are preventable, but the Asia-Pacific region has no regional 
prevention strategy; WHO recommendations for the 
region rely on passive case detection and case management 
alongside the use of long-lasting insecticidal nets.6 In 2012, 
Indonesia introduced a national screening policy for the 
prevention of malaria in pregnancy in malaria-endemic 
areas, the first country in Asia to do so. The single 
screening and treatment policy consists of screening all 
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pregnant women on their first antenatal care visit with 
either microscopy or a rapid diagnostic test and treatment 
of parasite-positive women with a first line antimalarial, 
followed by passive case detection and case management 
for the remainder of the pregnancy.7 High-grade resistance 
to sulfadoxine-pyrimethamine in Papua, Indonesia 
precludes the use of sulfadoxine-pyrimethamine for 
prevention or treatment of malaria.8
A three-arm, cluster-randomised, superiority trial 
(STOPMiP) was done in two sites in eastern Indonesia 
(Sumba island in Nusa Tenggara Province, and Mimika 
district in Papua Province) between May 16, 2013, and 
Nov 26, 2016.9 The trial compared the safety and efficacy of 
intermittent preventive treatment, consisting of monthly 
doses of an antimalarial in the second and third trimesters 
regardless of parasite positivity, and intermittent screening 
and treatment, consisting of screening at each scheduled 
antenatal care visit using a rapid diagnostic test and 
treatment with the first line antimalarial if parasite-
positive, with the current single screening and treatment 
strategy for control of malaria infection in pregnancy 
in Indonesia. The first-line anti-malarial for second and 
third trimesters, dihydroartemisinin-piperaquine,10 was 
used in all three groups. Cost-effectiveness, acceptability, 
and feasibility studies were done alongside the trial,11–13 
together with an evaluation of the implementation of 
single screening and treatment.13 Intermittent preventive 
treatment was effective at reducing maternal malaria 
infection and maternal anaemia in Papua but not in 
Sumba. The effect of intermittent screening and treatment 
with dihydroartemisinin-piperaquine compared with 
single screening and treatment was inconsistent. The 
authors concluded that the trial results do not support 
a role for intermittent screening and treatment with 
the current generation of standard rapid diagnostic tests 
or for intermittent preventive treatment in lower trans-
mission areas in the Asia-Pacific region. However, 
intermittent preventive treatment provides an efficacious 
intervention in Papua and similar areas with moderate-to-
high transmission in the region.10 In the accompanying 
single screening and treatment implementation feasibility 
study, around half of women were screened for malaria 
on their first visit to antenatal care. However, likelihood 
of malaria screening varied by level of health facility; 
screening was heavily skewed towards those accessing 
the community health centres with laboratory facilities 
(puskesmas) and poorly implemented at village-based 
health posts without microscopy (posyandus). In addition 
to the epidemiological, acceptability, and feasibility 
findings, the cost-effectiveness of alternative strategies for 
controlling malaria in pregnancy need to be understood. 
The aim of this study was to estimate the incremental 
Research in context
Evidence before this study 
A randomised controlled trial of interventions for the prevention 
of malaria in pregnancy in Papua, Indonesia, found intermittent 
preventive treatment with dihydroartemisinin-piperaquine to be 
a promising alternative to the current strategy of single 
screening and treatment. Acceptability and feasibility studies 
were also done in the same area as the trial to support policy 
decision making. These studies found that, although health 
providers and pregnant women widely accepted single screening 
and treatment, implementation was variable across different 
health facilities, particularly across different levels of facility. 
A change from screening and treatment strategies to preventive 
treatment would require a shift in attitude, particularly amongst 
health providers. Cost-effectiveness is another component of the 
policy decision-making process. This was the first trial of 
intermittent preventive treatment with dihydroartemisinin-
piperaquine in the Asia-Pacific region. A search of PubMed on 
June 4, 2020, with no date or language restrictions and using the 
search terms (“malaria” AND (“prevent*” OR “prevention”) AND 
“pregnan*” AND (“asia” OR “pacific”) AND (“economic” OR 
“economic evaluation” OR “cost-effect*”), confirmed that there 
are no published cost-effectiveness studies on preventive malaria 
infection in pregnancy interventions in the Asia-Pacific region.
Added value of this study
To our knowledge, this study is the first cost-effectiveness 
analysis of preventive strategies for malaria infection in 
pregnancy in the Asia-Pacific region, complementing the 
evidence generated from the first randomised controlled trial of 
intermittent preventive treatment in Indonesia. Along with the 
acceptability and feasibility studies nested within the trial, the 
cost-effectiveness results provide a comprehensive package of 
evidence on an alternative strategy to the existing single 
screening and treatment policy.
Implications of all the available evidence
Intermittent preventive treatment, as an alternative to single 
screening and treatment, is efficacious and cost-effective from 
a provider perspective. There was more acceptance of single 
screening and treatment (standard of care) amongst health 
providers due to the long-standing culture of testing and 
treating for malaria. However, the implementation of single 
screening and treatment was variable across levels of health 
facility. Conversely, pregnant women reported that they 
welcomed the opportunity to prevent malaria infections during 
pregnancy through intermittent preventive treatment to 
protect themselves and their babies. intermittent preventive 
treatment offers a cost-effective alternative to the current 
strategy of single screening and treatment for the prevention 
of the adverse effects of malaria infection in pregnancy in the 
context of the moderate malaria transmission setting of Papua, 
Indonesia. However, interventions to address provider and user 
acceptability should be considered alongside any future change 
in policy and costs and effects closely monitored. 
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cost-effectiveness of intermittent preventive treatment 
with dihydroartemisinin-piperaquine compared with 
single screening and treatment with dihydroartemisinin-
piperaquine in Papua, Indonesia.
Methods
Study design and participants
We did a cost-effectiveness analysis comparing inter-
mittent preventive treatment with dihydroartemisinin-
piperaquine with single screening and treatment 
with dihydro artemisinin-piperaquine using data from a 
cluster ran domised trial (STOPMiP). The trial enrolled 
1290 women from the site in southern Papua, Indonesia. 
Details of the trial methods were published previously.10 In 
brief, the units of randomisation were 21 health facilities 
providing antenatal care services with more than ten new 
pregnancies per year and assigned (1:1:1) to intermittent 
preventive treatment, intermittent screening and treat-
ment, or single screening and treatment. Women of 
all gravidities in the second or third trimester attending 
their first antenatal care clinic with a viable pregnancy 
of 16–30 weeks gestation were eligible for enrolment. 
Dihydroartemisinin-piperaquine was used in all three 
groups. Recruitment began on May 16, 2013, and the last 
infant follow-up was completed on Nov 26, 2016. All 
participants received a long-lasting insecticidal net at 
enrolment. The trial was registered with ISRCTN, number 
ISRCTN34010937.
The study received ethical approval from the Research 
Ethics Committees at the Eijkman Institute for Molecular 
Biology, Indonesia, and the Liverpool School of Tropical 
Medicine, UK. Endorsement was obtained from the 
Litbangkes (National Institutes of Health), Ministry of 
Health, Indonesia and deferral to the Liverpool School 
of Tropical Medicine Research Ethics Committees by 
the Research Ethics Committee of the London School 
of Hygiene and Tropical Medicine. Written, informed 
consent was obtained from each participant.
Outcomes
We included four trial outcomes in the mother or baby in 
the cost-effectiveness analysis: fetal loss or infant death 
by 6–8 weeks, low birthweight (<2500 g), moderate or 
severe anaemia (<9 g/dL), and clinical malaria during 
pregnancy. These outcomes were chosen based on 
clinical and economic importance and the availability of 
data for calculation of disability-adjusted life-years 
(DALYs). DALYs were calculated for each outcome in the 
intermittent preventive treatment and single screening 
and treatment trial groups.
Base case Range Distribution for 
probabilistic 
sensitivity 
analysis
Source
Cost estimates
Health worker time cost
Mean number of administrations of single screening and treatment 
with dihydroartemisinin-piperaquine per pregnancy
1 ·· Point estimate Ahmed et al (2019)10 
Administrations of single screening and treatment with positive rapid 
diagnostic test, n/N (%)
21/356 (5%) ·· Point estimate Ahmed et al (2019)10 
Time taken to provide one administration of single screening and 
treatment (negative rapid diagnostic test), min*
23 17·3–28·8 Gamma Observations
Time taken to provide one administration of single screening and 
treatment (positive rapid diagnostic test), min†
28 21–35 Gamma Observations
Mean number of administrations of intermittent preventive treatment 
with dihydroartemisinin-piperaquine per pregnancy
3·87 ·· Point estimate Ahmed et al (2019)10 
Time taken to provide one dose of intermittent preventive treatment, 
min‡
5 3·75–6·25 Gamma Observations
Midwife’s monthly cost of labour, 2016 US dollars $387·71 $332·26–$413·76 Gamma Health facility costings
Drug costs
Mean cost per dihydroartemisinin-piperaquine administration, 
2016 US dollars§
2·48 1·86–3·10 Gamma Ahmed et al (2019)10 
Average rapid diagnostic test cost per administration, 2016 US dollars¶ 0·86 0·65–1·08 Gamma Ahmed et al (2019)10 
Other costs
Reminder SMS or call for dihydroartemisinin-piperaquine dose 2 and 3, 
2016 US dollars
0·05 0·04–0·07 Gamma Ahmed et al (2019)10 
Costs from consequences
Cost per outpatient visit (excluding medical supplies), 2016 US dollars|| 9·23 7·38–12·30 Gamma Health facility costings
Cost per inpatient day (excluding medical supplies), 2016 US dollars|| 69·34 55·47–92·46 Gamma Health facility costings
Cost per paediatric inpatient day (excluding medical supplies), 
2016 US dollars||
69·34 55·47–92·46 Gamma Health facility costings
(Table 1 continues on next page)
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Statistical analysis
We calculated fixed and variable costs to the provider 
of delivering the interventions and costs of the four 
consequences of malaria infection in pregnancy for 
mother and infant included in the analysis using a 
combination of step-down costing and micro-costing.14,15 
We collected detailed cost data from seven antenatal 
care clinics in the Papua trial site between Feb 1 and 
May 31, 2016. The clinics were selected to provide a 
range of facility sizes in terms of the number of staff 
and number of consultations; all provided preventive 
and curative outpatient services, and one provided 
inpatient services. We used step-down costing to 
estimate the unit cost per outpatient consultation, per 
adult inpatient day, and per paediatric inpatient day. We 
calculated the weighted mean for each unit cost, based 
Base case Range Distribution for 
probabilistic 
sensitivity 
analysis
Source
(Continued from previous page)
DALY calculations
Discount rate 0·03 0·00–0·05 Point estimate Wilkinson (2016)20 
Neonatal outcomes
Life expectancy at birth, Indonesia (years) 69·72 68·5–70·95 Gamma GBD Study (2010)18
Length of disability—low birthweight, years 69·72 68·5–70·95 Gamma Salomon et al (2012)33
Disability weight—low birthweight 0·106 ·· Point estimate GBD Study (2004)17
Maternal outcomes
Mean age, years 26 ·· Point estimate Ahmed et al (2019)10 
Life expectancy for women aged 25–29 years, Indonesia, years 47·8 45·9–49·8 Gamma GBD Study (2010)18
Length of disability—malaria during pregnancy (5 days), years** 0·014 0·008–0·016 Gamma Webster et al (2018)13
Length of disability—anaemia during pregnancy (21 days), years 0·06 0·04–0·12 Gamma Price et al (2001)34
Disability weight—infectious disease severe acute episode 0·133 0·088–0·19 Gamma GBD Study (2017)19 
Disability weight—moderate anaemia 0·052 0·034–0·076 Gamma GBD Study (2017)19 
Mortality estimates
Case fatality rate for malaria during pregnancy 0·01% ·· Beta Brabin et al (2001)35
Case fatality rate for moderate or severe anaemia during pregnancy 0·0033% 0·0026%–0·0045% Beta Sicuri et al (2010)36
Measures of effect (trial outcomes)
Neonatal outcomes, per 1000 women
Risk of fetal loss or infant death at 6–8 weeks
Single screening and treatment group†† 35·1 16·4–53·9 Beta Ahmed et al (2019)10 
Intermittent preventive treatment group‡‡ 33·0 12·9–53·1 Beta Ahmed et al (2019)10 
Risk of low birthweight
Single screening and treatment group 129·8 94·0–165·6 Beta Ahmed et al (2019)10 
Intermittent preventive treatment group 115·2 77·1–153·4 Beta Ahmed et al (2019)10 
Maternal outcomes, per 1000 women
Risk of moderate or severe anaemia (<9 g/dL) at last antenatal care visit 
Single screening and treatment group 152·0 114·0–190·1 Beta Ahmed et al (2019)10 
Intermittent preventive treatment group 96·3 61·1–131·5 Beta Ahmed et al (2019)10 
Incidence of clinical malaria during pregnancy
Single screening and treatment group 36·5 17·0–56·0 Beta Ahmed et al (2019)10 
Intermittent preventive treatment group 6·3 0·0–14·9 Beta Ahmed et al (2019)10 
DALY=disability-adjusted life-year. *Based on observations of the trial team: 3 min per woman for group information session, plus 5 min for preparation of rapid diagnostic 
test and 15 min waiting for the result. †Based on observations of the trial team: 3 min per woman for group information session, plus 5 min for preparation of rapid 
diagnostic test, 15 min waiting for the result, and a 5 min counselling the patient about the treatment need for a positive rapid diagnostic test. ‡Based on observations of the 
trial team: 3 min per woman for group information session, plus 2 min for directly observed therapy of first dose of dihydroartemisinin-piperaquine. §Average dosing 
regimen of three tablets (40 mg dihydroartemisinin and 320 mg piperaquine) per day for 3 days based on patient weight range 36–75 kg; purchasing cost, including 
shipping, transport, wastage (+25%); same dosing regimen for intermittent preventive treatment, and a course of treatment for women found to be positive in the single 
screening and treatment group. ¶Purchasing cost, including shipping, transport, wastage (+25%). ||Weighted mean based on the number of consultations per facility; range 
represents variation in unit cost assuming ±25% consultations. **Median number of days loss of income reported by pregnant women during exit interviews used as a proxy. 
††In the single screening and treatment group, of the 13 fetal loss or infant deaths at 6–8 weeks, three were stillbirths (occurring after 28 weeks), two were miscarriages 
(occurring before 28 weeks), and eight were infant deaths. ‡‡In the Intermittent preventive treatment group, of the ten fetal losses or infant deaths at 6–8 weeks, four were 
stillbirths, one was a miscarriage, and five were infant deaths.
Table 1: Input variables for the base case and probabilistic cost-effectiveness of alternative interventions for malaria in pregnancy in Papua, Indonesia 
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on the number of consultations at facilities providing 
each service.
Where available, we used data from the trial area 
to estimate the costs of intervention delivery and 
consequences.10,13 Where data for a parameter were not 
available for the trial area, we extracted suitable estimates 
from the published literature (table 1; appendix p 1). All 
costs are presented in 2016 US dollars using the official 
average annual exchange rate (US$1=13 308 Indonesian 
Rupiahs).16
We did the cost-effectiveness analysis from the provider 
perspective, taking a lifetime horizon to show the lifelong 
(discounted) mortality effects of the consequences of 
malaria infection in pregnancy. We constructed separate 
but structurally identical decision trees for each of the 
four outcomes (appendix p 2).
We calculated DALYs for each outcome in each trial 
group separately using disability weights from the 2017, 
2010, and 2004 Global Burden of Disease studies,17–19 local 
life expectancies, no age weighting, and 3% discounting.20 
We calculated total DALYs in each trial group by 
summing the DALYs from the four outcomes, combining 
mortality (years of life lost) and morbidity (years lived 
with disability) effects. In the base case, fetal loss and 
infant deaths were assigned the same number of DALYs. 
For the total DALY calculation, only the morbidity effect 
(years lived with disability) of low birthweight was 
included to avoid double counting infant deaths 
attributable to low birthweight.
We calculated the incremental cost-effectiveness ratio 
for a hypothetical cohort of 1000 women by dividing the 
incremental cost of intermittent preventive treatment 
versus single screening and treatment by the incremental 
DALYs averted by intermittent preventive treatment 
versus single screening and treatment.
In a deterministic sensitivity analysis, we varied key 
variables and model assumptions one at a time, using the 
minimum and maximum values of the parameter range to 
explore their relative contribution to uncertainty in the 
incremental cost-effectiveness ratio estimate. To assess the 
uncertainty of all variables and assumptions simul-
taneously, we did a probabilistic sensitivity analysis with 
10 000 iterations, producing a point estimate and 95% CI 
based on percentiles for the difference in effects and costs 
and an average incremental cost-effectiveness ratio. Table 1 
provides a summary of the costs and effects parameters 
included in the cost-effectiveness analysis. A suitable 
distribution and range for each parameter are given to 
show the variability of each parameter and to define the 
boundaries for the sensitivity analysis.21 We plotted the 
results of the sensitivity analysis on the cost-effectiveness 
plane. We calculated the probability of intermittent pre-
ventive treatment with dihydroartemisinin-piperaquine 
being cost-effective for three cost-effectiveness thresholds: 
low (US$42), middle ($249), and high ($542) and plotted 
our results in a cost-effectiveness acceptability curve. The 
low and middle thresholds are historical WHO thresholds 
of $25 and $150, and the high threshold is a country-
specific estimate for Indonesia ($535),22 all inflated to 2016 
US dollars. We designed and ran the decision model in 
Microsoft Excel using Visual Basic for Applications to run 
the probabilistic sensitivity analysis.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and, with JW, had final 
responsibility for the decision to submit for publication.
Results
We included data on 675 women included in STOPMiP 
(319 in the intermittent preventive treatment group and 
356 in the single screening and treatment group). There 
were 35 fetal losses or infant deaths per 1000 women 
(95% CI 16–54) by 6–8 weeks in the single screening and 
treatment group and 33 per 1000 (13–53) in the inter-
mittent preventive treatment group, 130 (94–166) and 
115 (77–153) low-birthweight babies per 1000 women, 
152 (114–190) and 96 (61–131) cases of moderate or severe 
maternal anaemia per 1000 women, and 37 (17–56), and 
6 (0–15) episodes of clinical malaria during pregnancy 
per 1000 women (table 1). The frequency of all outcomes 
did not significantly differ between the two groups, 
except reduction in clinical malaria, which was 
significantly less common in the intermittent preventive 
treatment group.
The total cost per administration of single screening 
and treatment, including health worker time and 
supplies, was $4·69 (95% CI 4·00–5·46) when the rapid 
Cost, 2016 US dollars (95% CI)
Intervention cost
Total cost per administration of single screening and treatment if 
found positive
$4·69 (4·00–5·46)
Total cost per administration of single screening and treatment if 
found negative
$1·92 (1·59–2·27)
Total cost per administration of intermittent preventive treatment $2·76 (2·20–3·41)
Health provider cost of consequences
Mean cost per low birthweight $48·54 (26·09–76·32)
Mean cost per fetal death or infant death 6–8 weeks $0·00
Mean cost per case of moderate or severe anaemia $15·60 (10·76–22·17)
Mean cost per case of clinical malaria during pregnancy $46·09 (33·50–62·21)
Cost per 1000 pregnant women
Health provider cost of single screening and treatment, excluding 
consequences 
$2059·76 (1737·61–2423·50)  
Health provider cost of intermittent preventive treatment, excluding 
consequences 
$10 694·29 (8503·71–13 207·42)
Health provider cost of single screening and treatment, including 
consequences 
$12 415·34 (8919·93–16 950·09)
Health provider cost of intermittent preventive treatment, including 
consequences 
$18 079·62 (14 175·65–22 731·77)
Table 2: Costs of intervention and consequences of malaria in pregnancy in Papua, Indonesia
See Online for appendix
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diagnostic test was positive and $1·92 (1·59–2·27) if the 
rapid diagnostic test was negative; the total cost per 
administration of intermittent preventive treatment was 
$2·76 (2·20–3·41; table 2).
The average cost of health consequences of malaria 
infection in pregnancy was $48·54 (95% CI 26·09–76·32) 
for the short-term consequences per low-birthweight 
baby, $15·60 (10·76–22·17) per case of moderate or 
severe maternal anaemia, and $46·09 (33·50–62·21) per 
episode of clinical malaria during pregnancy.
The average cost per pregnant woman to deliver single 
screening and treatment was $2·06 (95% CI 1·74–2·42) 
and to deliver intermittent preventive treatment was 
$10·70 (8·50–13·21). This difference is largely driven by 
the greater number of administrations of intermittent 
preventive treatment per woman compared with single 
screening and treatment (3·87 vs 1·00). When the costs of 
consequences of malaria infection in pregnancy were 
included, the cost per 1000 pregnant women was $12 415·34 
(8919·93–16 950·09) for single screening and treatment, 
and $18 079·62 (14 175·65–22 731·77) for inter mittent 
preventive treatment (table 2). This amounts to intermittent 
preventive treatment costing on average around $5·66 
more per pregnant woman than single screening and 
treatment.
Compared with single screening and treatment, 
delivering intermittent preventive treatment to 1000 preg-
nant women led to 107·7 DALYs averted, of which 41·8% 
were due to low birthweight, 57·8% due to fetal loss or 
infant death by 6–8 weeks, and the remaining 0·4% due 
to maternal anaemia or clinical malaria. The incremental 
cost was $5664 per 1000 women, and the incremental 
cost-effectiveness ratio was $53 per DALY averted 
(table 3). Deterministic sensitivity analysis found that the 
cost-effectiveness of intermittent preventive treatment 
compared with single screening and treatment was most 
sensitive to the fetal loss or infant death effect measure, 
the discount rate used in the DALY calculations, and price 
of dihydroartemisinin-piperaquine (appendix pp 3–4). 
However, none of the parameter changes resulted in the 
incremental cost-effectiveness ratio increasing beyond 
the middle cost-effectiveness threshold.
The probabilistic sensitivity analysis for intermittent 
preventive treatment compared with single screening 
and treatment resulted in an incremental cost of $5657 
(95% CrI 1827 to 9448) and 107·4 incremental DALYs 
averted (–719·7 to 904·1) per 1000 women. The average 
incremental cost-effectiveness ratio was $53 per DALY 
averted (figure 1; table 3). The 95% CrI around the mean 
incremental cost-effectiveness ratio varied from $4 to to 
–$7 per DALY averted; the latter representing a situation 
in which intermittent preventive treatment costs more 
and incurs more DALYs than single screening and 
treatment. The probability of intermittent preventive 
treatment falling below the cost-effectiveness threshold 
of $42 and being considered highly cost-effective was 
48%; the probability of falling below the cost-effectiveness 
threshold of $249 was 59% or and below $542 was 60% 
(figure 2).
Discussion
Our findings suggest that intermittent preventive 
treatment with dihydroartemisinin-piperaquine at a cost 
of $53 per DALY averted offers a cost-effective alternative 
to the current policy of single screening and treatment in 
the moderate-malaria-transmission setting of Papua, 
Indonesia. Although intermittent preventive treatment 
incurred higher costs than single screening and treatment, 
it resulted in fewer DALYs. This cost per DALY compares 
favourably with the median cost per DALY averted by 
insecticide-treated nets ($30), intermittent preventive 
treatment with sulfadoxine-pyrimethamine ($27), and 
indoor residual spraying ($160) reported by White et al24 
(all figures inflated to 2016 US dollars for comparison); no 
studies were found from the Asia-Pacific region that were 
eligible for inclusion in these estimates.
The wide 95% CI in the incremental DALYs averted and 
incremental costs estimated by the probabilistic sensitivity 
analysis should be noted. There are simulation points in 
the northwestern quadrant of the cost-effectiveness plane 
Single screening and 
treatment
Intermittent preventive 
treatment
Base case
Δ DALYs—low birthweight ·· 45·1
Δ DALYs—fetal loss or infant death 
6–8 weeks
·· 62·3
Δ DALYs—maternal anaemia ·· 0·31
Δ DALYs—clinical malaria in pregnancy ·· 0·08
Total DALY 1429·5 1321·7
Total cost, 2016 US dollars* $12 415 $18 080
Δ Costs, 2016 US dollars* ·· $5664
Δ DALYs ·· 107·7
ICER, US dollars per DALY* ·· 53
Probabilistic sensitivity analysis
Δ DALYs (95% CrI)—low birthweight ·· 45·6 (–117·6 to 205·5)
Δ DALYs (95% CrI)—fetal loss or infant 
death at 6–8 weeks
·· 61·4 (–748·4 to 844·2)
Δ DALYs (95% CrI)—maternal anaemia ·· 0·31 (0·02 to 0·73)
Δ DALYs (95% CrI)—clinical malaria in 
pregnancy
·· 0·08 (0·03 to 0·15)
Total DALY (95% CrI) 1430·2 (944·2 to 2029·7) 1322·9 (812·7 to 1987·2)
Total cost (95% CrI), 2016 US dollars* $12 422 (8920 to 16 950) $18 079 (14 176 to 22 732)
Δ Costs (95% CrI), 2016 US dollars* ·· 5657 (1827 to 9448)
Δ DALYs (95% CrI) ·· 107·4 (–719·7 to 904·1)
Mean incremental cost-effectiveness 
ratio (95% CrI), US dollars per DALY*
·· 53 (4 to –7)†
DALY=disability-adjusted life-year. CrI=credible interval *Includes provider costs from health consequences. †The 
95% CrI varied from $4 to to –$7 per DALY averted; the latter representing a situation in which intermittent preventive 
treatment costs more and incurs more DALYs than single screening and treatment.
Table 3: Cost-effectiveness analysis, comparing intermittent preventive treatment with 
dihydroartemisinin-piperaquine with the existing policy of single screening and treatment in Papua, 
Indonesia
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and the uncertainty range of DALYs averted includes zero, 
indicating that, in some of the 10 000 iterations of the 
Monte Carlo model, intermittent preventive treatment 
incurred higher costs and resulted in more DALYs than 
single screening and treatment (ie, was more expensive 
and less effective). Although all four outcomes included 
in the cost-effectiveness analysis were less common in 
the intervention group than in the control group, only the 
reduction in clinical malaria between intermittent 
preventive treatment and single screening and treatment 
was statistically significant.
The cost-effectiveness acceptability curve presents the 
uncertainty in the model in an alternative format, showing 
the probability of intermittent preventive treatment falling 
below certain cost-effectiveness thresholds. To support 
decision-makers in choosing actions that are likely to lead 
to population health improvements, cost-effective ness 
analyses should compare the additional health benefits of 
an intervention with the health likely to be lost elsewhere 
as a consequence of any additional costs (ie, the health 
opportunity costs). Cost-effectiveness thresholds are 
intended to represent these health oppor tunity costs; a 
number of options exist, each with advantages and 
disadvantages.25 For example, the historic thresholds of 
$25 and $150 (adjusted in this study to $42 and $249) were 
based on affordability expectations and are widely used 
irrespective of the local context.26 Another widely used 
threshold is 1–3 times a country’s per capita GDP, 
essentially taking a human capital approach to valuing a 
person’s life by the economic activity of individuals.27 
Ochalek et al22 argue that, with these demand-side cost-
effectiveness thresholds of what health expenditure ought 
to be, there is no guarantee they will reflect actual health 
opportunity costs and their use, therefore, risks reducing, 
rather than improving, population health. They instead 
propose the use of supply-side thresholds of health 
opportunity costs given actual expenditure. Ochalek et al22 
used econometric models analysing the effect of health 
expenditure on health outcomes from cross-country data 
to estimate supply-side cost-effectiveness thresholds for 
countries without empirical data; here we used their 
estimate for Indonesia of $542. The probability of inter-
mittent preventive treatment falling below the low cost-
effectiveness threshold of $42 was 48%; the probability 
of intermittent preventive treatment falling below the 
middle and high cost-effectiveness thresholds included in 
this analysis ($249 and $542) was consistent at around 
60%, reflecting that above a cost-effectiveness threshold 
of around $250, there is no additional increase in the 
probability of intermittent preventive treatment being 
cost-effective. Therefore, use of the considerably higher 
one-times per capita GDP threshold ($3604 for Indonesia 
in 2016)16 would not increase the probability of inter-
mittent preventive treatment being cost-effective in 
this analysis.
The uncertainty in the model should be noted. The trial 
was designed to detect a reduction in maternal or placental 
Figure 1: Cost-effectiveness plane of intermittent preventive treatment versus single screening and 
treatment in Papua, Indonesia
The graph displays results of Monte Carlo simulations with 10 000 iterations using the value ranges and 
distributions presented in table 1. The horizontal axis represents the difference in effect between intermittent 
preventive treatment and single screening and treatment and the vertical axis represents the difference in cost. 
The incremental cost-effectiveness ratio for each simulation is defined as the slope of the line from the origin to 
that datapoint. The red dot represents the mean incremental cost-effectiveness ratio ($53 per DALY averted) at a 
mean cost of $5657 and a mean of 107 DALYs averted. Because $53 per DALY averted lies northeast of the origin 
and is a positive number, the new intervention is more effective but also more costly than the existing strategy. 
Datapoints falling northwest of the origin indicate the possibility that the new intervention is less effective and 
more costly than the existing strategy. Dashed lines indicate the 2·5th and 97·5th percentiles used to estimate the 
95% CI for the incremental cost-effectiveness ratio. The lower bound of the 95% CI was $4 per DALY averted, at a 
cost of $2124 and 553 DALYs averted. The upper bound of the 95% CI was –$7 per DALY averted, at a cost of $3120 
and –472 DALYs averted (i.e. health loss from the new strategy).
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malaria infection at delivery. It was not powered to detect 
statistically significant differences in the clinical outcomes 
included in this cost-effectiveness analysis, and the wide 
confidence interval in the effect size for some of these 
outcomes is reflected in the CI around the cost-
effectiveness analysis.15 Cost-effectiveness analysis is 
valuable to decision-makers, as long as the uncertainty 
reflected by the results of the probabilistic sensitivity 
analysis is taken into account. In Papua, Indonesia, the 
malaria transmission intensity is similar to those in 
moderate malaria transmission areas in Africa where 
intermittent preventive treatment with sulfadoxine-
pyrimethamine is implemented. It is biologically plausible 
that effective chemoprevention with monthly intermittent 
preventive treatment could reduce low birthweight and 
fetal or neonatal death in Papua when compared with 
single screening and treatment with low sensitivity rapid 
diagnostic tests.10 Therefore, although the cost per capita 
of delivering intermittent preventive treatment ($10·70) is 
higher than the current strategy of single screening and 
treatment ($2·06), it is a feasibly efficacious strategy for 
the chemoprevention of adverse pregnancy outcomes in 
the context of the moderate malaria transmission intensity 
found in Papua. Furthermore, the cost per capita of 
intermittent preventive treatment relates favourably to the 
total per capita annual health expenditure of $112 in 
Indonesia.23 Although sulfadoxine-pyrimethamine is a 
cheaper drug than dihydroartemisinin-piperaquine, use 
of sulfadoxine-pyrimethamine for intermittent preventive 
treatment is not an option in Papua owing to high-grade 
resistance.28,29
Fetal deaths were allocated the same number of years 
of life lost as infant deaths. The incremental cost-
effectiveness ratio was very sensitive to this assumption, 
particularly owing to the small numbers of events in each 
group and the high proportional contribution of infant 
outcomes to the total DALYs. However, the majority 
of these fetal losses were stillbirths, taking place at 
28 weeks gestation or later and we took this approach 
to acknowledge the value of the loss of a baby late in 
pregnancy as supported by the 2016 Lancet Series on 
Ending Preventable Stillbirths,30 which advocates for the 
recognition of the full impact of stillbirth and the need 
for improved measurement and reporting.
Our model had several limitations. Although the effect 
parameters used were from an intention-to-treat analysis 
rather than per protocol, efficacy outcomes from a 
controlled trial will still be better than results achievable 
under routine conditions. For example, although around 
90% of women in Papua attend antenatal care clinics at 
least once, only 45% of women make at least four 
antenatal care visits.31 In contrast, women in our study 
received on average 3·9 administrations of intermittent 
preventive treatment. It would be possible to model the 
change in costs of varying numbers of administrations of 
intermittent preventive treatment, because we know the 
unit costs per administration. However, there are no data 
on how efficacy would be affected by varying the number 
of administrations, and hence the number of courses 
administered in our trial were used. A similar limitation 
applies to the low sensitivity of the rapid diagnostic tests 
used. It would be useful to explore the effects of 
increasing the proportion of rapid diagnostic tests that 
were positive as a proxy for more sensitive rapid 
diagnostic tests in future. However, it is not possible to 
predict the resulting change in efficacy given the available 
evidence.
Our analysis presents the provider perspective only. 
Taking a societal perspective would capture the full 
costs associated with the delivery of the interventions 
and the consequences of malaria infection in pregnancy, 
including the direct and indirect costs of seeking and 
receiving care. However, estimating the medical costs 
of malaria infection in pregnancy to the provider or 
household, particularly low birthweight and fetal or 
neonatal loss, is challenging due to the wide variation in 
treatment required and would have increased uncertainty 
in the model estimates. Despite intermittent preventive 
treatment requiring monthly dosing compared with one 
administration of single screening and treatment, the 
monthly doses align with the antenatal care schedule, 
and would therefore, in theory, not require extra visits 
or incur incremental costs to households. However, as 
previously discussed, only 45% of women made at least 
four antenatal care visits in Papua, which suggests 
interventions to increase antenatal care attendance 
might be needed, which would incur additional costs to 
providers and households. This could be an area for 
future research.
Decisions about a change in policy for the prevention 
of malaria infection in pregnancy will be based on 
multiple factors in addition to effectiveness and cost-
effectiveness, including equity, ethics, acceptability, 
feasibility and a range of other factors affecting the 
political economy. Studies done in the same area as ours 
found that the existing strategy of single screening and 
treatment was acceptable to health providers but being 
implemented inconsistently.11,13 Investigation of the 
acceptability of intermittent screening and treatment or 
intermittent preventive treatment as alternatives to the 
existing strategy found that there was more acceptance of 
intermittent screening and treatment among health 
providers due to the long-standing culture of testing and 
treating for malaria. Conversely, pregnant women were 
accepting of all three interventions used in the trial and 
reported that they welcomed the opportunity to prevent 
malaria infections during pregnancy through inter-
mittent pre ven tive treatment to protect themselves and 
their babies.12 Concerns about the presumptive use of 
dihydro artemisinin-piperaquine during pregnancy were 
however revealed during the trial; a higher proportion of 
participants withdrew consent in the intermittent 
preventive treatment group (14% compared with 2% in 
the single screening and treatment group and 0% in the 
Articles
www.thelancet.com/lancetgh   Vol 8   December 2020 e1532
intermittent screening and treatment group).10 Although 
the occurrence of adverse events was similar across trial 
groups, the larger number of withdrawals in the 
intermittent preventive treatment group reflects women’s 
concerns about side-effects and taking medications when 
they are pregnant while they do not have any symptoms 
of malaria. The withdrawals occurred in certain clusters 
often led by one influential woman. Similarly, although 
adherence to the full dose of dihydroartemisinin-
piperaquine was high (90%) in the trial setting, adherence 
will probably be lower under routine conditions.32 Inter-
ventions to encourage uptake and correct implementation 
of any new policy will increase the potential impact of the 
intervention when delivered under routine conditions, 
and the costs of these interventions should be factored 
into future cost-effectiveness analyses.
Intermittent preventive treatment is likely to offer a 
cost-effective alternative to the current strategy of single 
screening and treatment for the prevention of the 
adverse effects of malaria infection in pregnancy in the 
context of moderate malaria transmission in Papua, 
Indonesia. Interventions to address provider and user 
acceptability should be considered alongside any future 
change in policy and costs and effects closely monitored.
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